Premium
Recent Chemotherapy for Child Pneunomia and Empyema
Author(s) -
Uehara Suzuko,
Nakamura Akira,
Himi Kyoko,
Namba Mami,
Matsumura Chieko,
Suzuki Hiroshi,
Ishikawa Nobuyasu
Publication year - 1986
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.1986.tb00753.x
Subject(s) - medicine , ampicillin , pneumonia , antimicrobial , antimicrobial chemotherapy , penicillin , streptococcus pneumoniae , antibiotics , chemotherapy , empyema , microbiology and biotechnology , intensive care medicine , surgery , biology
Abstract Recent progress in chemotherapy has contributed to the remarkable decrease in mortality from pneumonia in infancy and childhood; however, wide use of antimicrobials has resulted in incapability of etiologic diagnosis. Appropriate chemotherapy for pneumonia should be initiated based on the relative frequency of causative organisms related to age groups, and their antimicrobial susceptibility. Therapeutic development should be reevaluated by the pathogens isolated prior to antimicrobial administration. S. aureus is the most important causative agent in fatal cases of pneumonia. Judging from our studies on offending bacteria in bronchopulmonary infections, H. influenzae, S. pneumoniae and S. aureus are the major pathogens in pneumonia. Therefore, the main initial antimicrobials in uncompromised infants and children should be ampicillin (plus penicillinase‐resistant penicillin) covering these organisms. Methicillin‐resistant S. aureus , ampicillin‐resistant H influenzae and penicillin‐resistant S. penumoniae are of great concern. Chemotherapy for these strains is discussed. Treatment with macrolides is mainly recommended for M. pneumoniae . Chemotherapeutic results of treatment of C. trachomatis will be elucidated in a few years.